Trust Co raised its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 13.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,634 shares of the pharmaceutical company’s stock after buying an additional 3,285 shares during the period. Trust Co’s holdings in GlaxoSmithKline were worth $1,163,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Wealthcare Advisory Partners LLC increased its stake in shares of GlaxoSmithKline by 1,982.8% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after acquiring an additional 3,351 shares in the last quarter. FTB Advisors Inc. lifted its holdings in GlaxoSmithKline by 16.9% during the second quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after purchasing an additional 539 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in GlaxoSmithKline by 3.5% during the second quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after purchasing an additional 148 shares in the last quarter. Advisory Services Network LLC lifted its holdings in GlaxoSmithKline by 24.2% during the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after purchasing an additional 788 shares in the last quarter. Finally, Coastline Trust Co purchased a new position in GlaxoSmithKline during the second quarter valued at approximately $202,000. 9.80% of the stock is owned by hedge funds and other institutional investors.
GlaxoSmithKline plc (GSK) traded down $0.13 during mid-day trading on Thursday, reaching $38.02. 3,040,000 shares of the company’s stock were exchanged, compared to its average volume of 5,510,000. The company has a market capitalization of $92,850.00, a PE ratio of 29.02, a price-to-earnings-growth ratio of 2.17 and a beta of 0.97. GlaxoSmithKline plc has a fifty-two week low of $34.52 and a fifty-two week high of $44.53. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.85 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%. equities research analysts forecast that GlaxoSmithKline plc will post 2.9 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, January 11th. Investors of record on Friday, November 10th were issued a $0.5037 dividend. This represents a $2.01 annualized dividend and a yield of 5.30%. The ex-dividend date of this dividend was Thursday, November 9th. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio is 155.73%.
Several equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Wednesday. Barclays raised shares of GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a report on Tuesday. UBS Group reissued a “buy” rating on shares of GlaxoSmithKline in a report on Monday. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, January 11th. Finally, ValuEngine downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Three analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $38.57.
In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were acquired at an average price of $14.00 per share, with a total value of $5,999,994.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 10.00% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/18/glaxosmithkline-plc-gsk-position-lifted-by-trust-co.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.